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Abstract. A synthetic lipid A analog (ONO-4007) exhibits antileishmanial activity by activating Leishmania-infected
macrophages in experimental leishmaniasis. In the present in vitro study, ONO-4007 at concentrations between 0.01 and
1.00 mg/mL markedly inhibited the proliferation of Leishmania major and L. amazonensis promastigotes. Ultrastruc-
turally, L. major-infected macrophages showed degenerated intracellular amastigotes after exposure to ONO-4007.
Leishmania-infected macrophages treated with ONO-4007 showed poorly developed parasitophorous vacuoles. High
levels of tumor necrosis factor-alpha were induced by ONO-4007 in Leishmania-infected macrophages. In this in vivo
study, L. amazonensis-infected BALB/c mice were treated with a dose of 30 mg/kg of ONO-4007 by perilesional and
peritoneal injections. The skin lesion size was assessed before treatment with ONO-4007 and at eight weeks after
injection. The lesion size was significantly suppressed in mice perilesionally injected with ONO-4007 (P < 0.01) compared
with the controls. The data from our present in vitro and in vivo studies indicate that ONO-4007 has an antileishmanial
effect.
INTRODUCTION
Leishmaniasis is a widespread, infectious parasitic disease
caused by Leishmania spp. The World Health Organization
estimates that 350 million people are at risk of infection with
leishmaniasis in endemic areas and that approximately 12 mil-
lion are currently infected, with 400,000 new cases each
year.1,2 It is now a worldwide problem and a great challenge
exists in the fight against this disease. At the present time,
commercially available, antimonial compounds remain the
first-line drugs of choice in spite of reported severe toxicity
affecting the heart, liver, and kidneys.3 However, instead of
using metallic antimonial agents in the treatment of leishma-
niasis, investigators have been introducing different chemo-
therapeutic agents with different methods of administration.4
Studies in endemic areas have reported strains of Leishmania
that are resistant to antimonial compounds.3,5 Safe, effective,
and sensitive chemotherapeutic agents that kill Leishmania
parasites have been the subjects of intense research to dis-
cover new drugs for solving this worldwide health problem.
ONO-4007, a novel synthetic lipid A analog, has been re-
ported to exhibit strong antitumor activity in various experi-
mental animal models via intratumor production of the tumor
necrosis factor-alpha (TNF-) with lower toxicity than has
been exhibited with bacterial lipopolysaccharide (LPS).6
Lipid A is an active part of LPS, a component of the cell wall
of gram-negative bacteria that has a variety of biologic activi-
ties, including both beneficial immunopotentiating activity
and toxicity.7,8 The chemical structure of ONO-4007 (sodium-
2-deoxy-2[3S-(9-phenylnonanoyloxy)tetradecanoyl]-amino-
3-0-(9-phenylnonanoyl)-D-glucopyranose 4-sulfate) is shown
in Figure 1. This analog activates macrophages, which then
release large amounts of TNF- in a dose-dependant man-
ner.9,10 Moreover, in vitro studies have shown that pretreat-
ment of human monocytes with granulocyte-macrophage
colony-stimulating factor enhances the production of TNF-
in response to ONO-4007.11 It has been reported that ONO-
4007 contributes to the induction of nitric oxide (NO) syn-
thase in macrophage cell lines J774.2, resulting in the forma-
tion of cytotoxic NO, which may show antitumor activity
in vitro.12
Macrophages are activated when exposed to cytokines to
eliminate intracellular infections by microorganisms.13 In in-
fections with Leishmania, cytokines such as interferon-
gamma (IFN-), migration inhibitory factor, and TNF- are
capable of inducing leishmaniacidal activity in vitro.15–20 The
leishmaniacidal activity of macrophages is also mediated by
NO21 after activation by cytokines and LPS.21,22 These data
indicate that ONO-4007 may contribute to the elimination of
Leishmania parasites from infected subjects.
In this study, we examined the antileishmanial efficacy of
ONO-4007 in experimental leishmaniasis in vitro and in vivo,
with the aim of introducing a new drug strategy for treatment
of leishmaniasis. The inhibitory effects of ONO-4007 on
Leishmania proliferation were investigated in promastigotes
and amastigotes, and in L. amazonensis-infected BALB/c
mice.
MATERIALS AND METHODS
In vitro study. Parasites. Two strains of Leishmania pro-
mastigotes, L. major (MHOM/SU/73/5ASKH) and L. ama-
zonensis (MHOM/BR/73/M2269), were cultured in RPMI
1640 medium (GIBCO-BRL, Tokyo, Japan) medium supple-
mented with 10% fetal bovine serum (FBS), 50 units/mL of
penicillin, and 50 g/mL of streptomycin.
Macrophage culture.Macrophage cell line J774 was ob-
tained from the Dai Nippon Pharmaceutical Co. (Osaka, Ja-
pan), and was cultured in Dulbecco’s minimal essential me-
dium (GIBCO-BRL) supplemented with 10% FBS, 50 units/
mL of penicillin, and 50 g/mL of streptomycin. Laboratory-
Tek® tissue culture chamber slides (Nalge Nunc International
Corp., Naperville, IL) were used for cell culture and kept in
an incubator at 37°C in an atmosphere of 5% CO2 and a
humidity of 95%.
Drug. ONO-4007 was generously provided by the Ono
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Pharmaceutical Co. (Osaka, Japan). The drug was prepared
in 5% ethanol in a 4.5% glucose solution.
Drug administration. Promastigotes of L. major and L.
amazonensis were exposed to ONO-4007 at concentrations of
0 mg/mL, 0.01 mg/mL, 0.10 mg/mL and 1.00 mg/mL for 48
hours. Similarly, macrophages infected with L. major were
incubated with ONO-4007 at the same dosages for 48 hours.
Parasite count. Promastigotes in the medium were counted
with a hemocytometer.
Enzyme-linked immunosorbent assay (ELISA) for TNF-..
The expression of TNF- in culture supernatants was deter-
mined by a sandwich ELISA using a commercially available
TNF- kit (Endogen, Woburn, MA) according to the proto-
col provided by the manufacturer. The level of TNF- was
expressed as micrograms per milliliter/2.08 × 106 macrophage
cells. All measurements were carried out in triplicate.
Electron microscopy. Macrophages were harvested and
washed twice with phosphate-buffered saline. They were
fixed with 2% glutaraldehyde in 0.1 M cacodylate buffer, and
then treated with phosphate-buffered 1% osmium tetroxide
for one hour. The samples were dehydrated with a graded
ethanol series and propylene oxide. The samples were then
embedded in Epon 812 resin and ultrathin sections were cut.
The sections were stained with uranyl acetate, counterstained
with lead citrate, and then observed with a JEOL 2000EX
electron microscope (JEOL, Tokyo, Japan).
In vivo study. Infection of mice with parasites. Female
BALB/c mice (6−8 weeks old) were used in these experi-
ments. They were strictly maintained under the rules and
regulations of the Animal Welfare Center (University of the
Ryukyus, Okinawa, Japan) in specific pathogen-free condi-
tions with laminal air flow. All mice were inoculated intrad-
ermally on the shaved skin of their backs with 2 × 107 L.
amazonensis promastigotes.
Drug administration.After the skin lesion was confirmed
(five weeks after inoculation), a 30 mg/kg dose of ONO-4007
was perilesionally or peritoneally injected into the mice twice
a week for eight consecutive weeks. Mice were divided into
four groups: group A (vehicle only, perilesional injection, n
7), group B (vehicle only, peritoneal injection, n 8), group
C (ONO-4007, perilesional injection, n  6), and group D
(ONO-4007 peritoneal injection, n  6).
Assessment of the lesion size. Lesion size was measured
with a dial caliper before and after eight weeks of treatment
with ONO-4007 and expressed as the area of lesion (long axis
× short axis in mm2).
Statistical analysis. Statistical differences were examined by
the unpaired t-test. The level of significance was determined
at P < 0.05.
FIGURE 1. Chemical structure of ONO-4007.
FIGURE 2. Inhibition of growth of Leishmania promastigotes in
culture medium incubated with ONO-4007. Promastiogotes of L. ma-
jor (A) and L. amazonensis (B) showed a gradual reduction in num-
bers when exposed to 0.01–1.00 mg/mL of ONO-4007 for 48 hours.
Both strains of promastigotes proliferated in the absence of ONO-
4007. A significant reduction in number of promastigotes was ob-
served following incubation with the drug for 24–48 hours. The pro-
liferation of L. major and L. amazonensis was inhibited by ONO-
4007. Bars show the mean ± SD of four experiments.
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RESULTS
Anti-promastigote activity of ONO-4007. Promastigotes of
L. major and L. amazonensis were cultured with 0, 0.01, 0.10,
and 1.00 mg/mL of ONO-4007 for 48 hours. In the absence of
ONO-4007, both strains of Leishmania promastigotes prolif-
erated over time. In contrast, both types of promastigotes
treated with ONO-4007 gradually decreased in number in a
time-dependent fashion. After 24 and 48 hours of incubation
with three different drug concentrations, L. major promasti-
gotes showed a significant reduction in number when com-
pared with the controls. No significant differences in the num-
ber of L. major promastigotes were observed for the three
different concentrations of drug after 48 hours of incubation
(Figure 2A). However, the number of L. amazonensis pro-
mastigotes was significantly reduced at the three different
drug concentrations when compared with the controls follow-
ing incubation for 24 and 48 hours (Figure 2B). Statistically
significant differences were observed at a concentration of
1.00 mg/mL compared with 0.01 mg/mL (P < 0.01) and at a
concentration of 1.00 mg/mL compared with 0.10 mg/mL fol-
lowing 48 hours of incubation (P < 0.01). These results dem-
onstrate the inhibition of the growth of L. major and L. ama-
zonensis promastigotes by ONO-4007.
Promastigotes cocultured with macrophages. This study
was performed to estimate the time required for Leishmania
promastigotes to enter murine macrophages. Cocultivation
showed that approximately 80% of the promastigotes of L.
major and L. amazonensis in the medium entered macro-
phages after 24 hours (Figure 3). Thus, ONO-4007 should be
given after 24 hours of cocultivation with the macrophages.
Expression of TNF- by L. major-infected macrophages.
Production of TNF- by macrophages infected with L. major
following incubation for 24 hours with three concentrations
(0.01 mg/mL, 0.10 mg/mL, and 1.00 mg/mL) was examined by
sandwich ELISA. The culture supernatant was collected and
analyzed after incubation for 6, 12, and 24 hours with ONO-
4007. Production of TNF- was significantly induced by
ONO-4007 at all three concentrations. The highest level of
TNF- was observed after incubation for six hours with all
concentrations of drug, and gradually decreased in a time-
dependent manner (Figure 4). After incubation for six hours,
the level of TNF- was significantly higher at drug concen-
trations of 0.01 mg/mL, 0.10 mg/mL, and 1.00 mg/mL when
compared with the controls (P < 0.01, P < 0.001, and P < 0.01,
respectively). Induction of TNF- after incubation for six
hours at ONO-4007 concentrations of 0.01 mg/mL and 0.10
mg/mL was higher than at the concentration of 1.00 mg/mL.
Electron microscopy of L. major-infected macrophages.
Macrophages in the absence of ONO-4007 showed many in-
tracellular amastigotes within markedly large parasito-
phorous vacuoles (Figure 5A). At a higher magnification,
oval amastigotes showed well-developed cell organelles (Fig-
ure 5C). Conversely, macrophages treated with ONO-4007
showed only a few amastigotes and poorly formed parasito-
phorous vacuoles in the macrophages (Figure 5B). At a
higher magnification, intracellular amastigotes showed de-
generative changes and poorly formed parasitophorous vacu-
oles (Figure 5D).
Lesion development in L. amazonensis-infected mice.
BALB/c mice infected on their backs with L. amazonensis
promastigotes showed skin lesions as a single nodule with or
without ulceration five weeks after inoculation. The lesions
developed to full size in most of the infected mice. However,
FIGURE 3. Numbers of Leishmania major and L. amazonensis
promastigotes in culture medium cocultured with J774 macrophages.
Both strains of Leishmania promastigotes show a gradual reduction
in number. After 24 hours of cocultivation, a reduction of approxi-
mately 80% in number of promastigotes in both strains is observed,
which indicates that approximately 80% of the initial inoculated pro-
mastigotes have entered the macrophages. Bars show the mean ± SD
of four experiments.
FIGURE 4. Production of tumor necrosis factor-alpha (TNF-) by
Leishmania major−infected macrophages in response to three differ-
ent concentrations of ONO-4007 (0.01 mg/mL, 0.10 mg/mL, and 1.00
mg/mL). The cells were cocultured with L. major for 24 hours and
then incubated with three concentrations of ONO-4007 for 6, 12, and
24 hours. Production of TNF- by L. major-infected macrophages
was calculated per 2.08 × 106 macrophages. The high level of TNF-
production was observed after incubation for six hours at three dif-
ferent concentrations. All measurements were carried out in tripli-
cate. Bars show the mean ± SD. Statistical analysis was performed to
compare the controls with three different concentrations of
ONO4007 after incubation for 6, 12, and 24 hours. *P < 0.001; **P <
0.01; ***P < 0.05.
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FIGURE 5. Ultrastructure of Leishmania major−infected macrophages. A, L. major-infected macrophages used as a control shows large
parasitophorous vacuoles (P) containing many Leishmania parasites (arrows). B, an L. major-infected macrophage treated with ONO-4007
contains a single Leishmania parasite (arrows), but parasitophorous vacuoles are too small to identify. C, Higher magnification view of control
macrophages, showing formation of a parasitophorous vacuole with a well-developed membrane (arrowhead). D, Higher magnification of
macrophages treated with ONO-4007, showing poor formation of parasitophorous vacuoles compared with the control (arrowhead) and an
amastigote (Am) inside the parasitophorous vacuole with degenerative changes.
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four mice in group C (ONO-4007 perilesionally injected mice)
showed healed lesions eight weeks after treatment (Figure
6C). The mean (SD) size of the skin lesions in each group is
shown in Figure 7. Lesion development was significantly sup-
pressed in mice perilesionally injected with ONO-4007 (P <
0.01) compared with mice injected with the vehicle (group A).
No statistically significant difference in lesions was observed
between mice peritoneally injected with ONO-4007 (group
D) and mice injected with the vehicle (group B).
DISCUSSION
This study provides evidence that ONO-4007 inhibits pro-
mastigote proliferation. However, in the elimination of Leish-
mania parasites in vivo, activation of macrophages may be the
most critical factor because the disease course is influenced by
several cytokines.23–26 Activation of macrophages can esti-
mated by endogenous production of TNF- and confirmed by
ultrastructural findings, such as well-developed mitochondria,
endoplasmic reticulum, and other cell organelles. In previous
reports, ONO-4007 induced higher levels of endogenous
production of TNF- and cytocidal activities against MM46
mammary/KDH-8 hepatoma cells than LPS in vitro and
in vivo.6,11
In the present study, ONO-4007 induced production of
TNF- in Leishmania-infected macrophages at concentra-
tions of 0.01–1.00 mg/mL, especially at 0.10 mg/mL. Tumor
necrosis factor-alpha is also a pleotrophic cytokine that may
stimulate a variety of potent antimicrobial mechanisms27,28
and have a protective role against infection with L. major.18,19
Our ultrastructural observations of Leishmania-infected mac-
rophages treated with ONO-4007 revealed degenerative
change in amastigotes, dilated rough endoplasmic reticulum,
and large mitochondria. These results supported our theory
that ONO-4007 promotes antileishmanial activity by activa-
tion of Leishmania-infected macrophages. Ultrastructural
study showed that in the ONO-4007-treated macrophages,
the number of amastigotes was much less than in the controls.
FIGURE 6. Area (long axis × short axis in mm2) of skin lesions of Leishmania amazonensis−infected BALB/c mice before and after eight weeks
treatment with ONO-4007. A, Mice in group A (n 7) were perilesionally injected with vehicle. B, Mice in group B (n 8) were peritoneally
injected with vehicle. C, Mice in group C (n 6) were perilesionally injected with ONO-4007 (note that the lesions healed in four mice). D, Mice
in group D (n  6) were peritoneally injected with ONO-4007.
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The most striking feature of the study was the formation of
parasitophorous vacuoles in the infected macrophages. The
parasitophorous vacuoles were very large in cells not treated
with ONO-4007, and they contained several amastigotes. In
contrast, cells treated with ONO-4007 cells did not show ex-
tensive formation of these vacuoles. Parasitophorous vacu-
oles are a sign of intracellular parasite survival.29 Poor for-
mation of these vacuoles in cells treated with ONO-4007 cells
suggests that amastigote activity was inhibited by the treat-
ment.
In our in vitro study, we used ONO-4007 in a murine model
of leishmanisis. After checking the development of lesions,
we injected this drug perilesionally and peritoneally. In mice
injected perilesionally with ONO-4007 (group C), lesion de-
velopment was significantly suppressed compared with the
controls (group A). It is noteworthy that four mice in group C
showed healed lesions, although lesion development in these
mice was variable. In the peritoneally injected group, there
was no significant difference between the drug and control
groups. These results suggests that ONO-4007 might have an
antileishmanial effect in the in vivo model, as well as in the in
vitro model. The toxic effect of ONO-4007 was very negli-
gible, a 1,000-fold less than that of Escherichia coli LPS. This
has been shown in previous reports.6,10,11 In human mono-
cytes/macrophages, ONO-4007 stimulates higher levels of
TNF- production with lower toxicity than bacterial LPS.11
Lipopolysaccharide has never been used in humans due to its
strong toxicity. Based on these observations, ONO-4007 may
be a practical therapeutic agent for treatment of leishmania-
sis. We used only one dose (30 mg/kg) of the drug in the in
vivo study. Several dosage levels should be tested in mice in
future studies.
Killing of intracellular parasites by macrophages has been
shown to be mediated by NO both in vitro30,31 and in vivo.31
Recent studies have shown that NO is a potent antimicrobial
agent21 derived from L-arginine by the enzyme NO syn-
thase.32,33 The cytokines TNF- and IFN- are the important
immunologic mediators in the induction of NO synthase in
macrophages.34,35 The conversion of L-arginine to NO is cata-
lyzed by the enzyme NO synthase, which is induced in mac-
rophages after activation of cytokines by LPS.21,22 The Th1
cytokine response and the production of IFN-25,26 are re-
quired for the induction of inducible NO synthase in infected
macrophages.30,31,36 ONO-4007 induced NO synthase result-
ing in the formation of cytotoxic NO, which may contribute to
the antitumor activity that has been shown in both in vivo and
in vitro studies.12 It has been reported that intracellular killing
of Leishmania parasites within macrophages was enhanced in
the presence of TNF- together with IFN- or LPS.14,19 Nei-
ther IFN- nor LPS alone induced leishmaniacidal activities
in vitro, indicating that LPS was necessary as a secondary
stimulus.17 Although our experiment was not specifically de-
signed to determine the exact mechanism(s) by which ONO-
4007 exerted an antileishmanial agent, it is suggested that the
role of NO and Th1 cytokine induction should be the subject
of intense research in further in vivo studies using experimen-
tal leishmanial mice.
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